Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa
Epix Medical of Cambridge, MA, has filed a registration statementwith the Securities and Exchange Commission for an initial publicoffering of two million shares of stock, plus an overallotmentoption of 300,000 shares. Epix, formerly known as Metasyn, isa developer of targeted contrast agents, including MS-325, a gadolinium-basedagent for MR angiography of coronary and peripheral arteries.
Epix has licensed rights to MS-325 and other MRI vascular agentsin all countries except Japan to Mallinckrodt of St. Louis (SCAN10/9/96). MS-325 has entered phase I clinical trials, and proceedsfrom Epix's IPO will help fund that work and will be used forgeneral corporate purposes.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.